Curis Inc. (NASDAQ:CRIS) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants James Dentzer – President & Chief Executive Officer Bill Steinkrauss – Chief Financial Officer & Chief Administrative Officer Bob Martell – Head of R&D Conference Call Participants Alethia Young – Cantor Fitzgerald Edward White – HC Wainwright Yale Jen – Laidlaw and Company Danya Ben-Hail – Jones Trading Dane Leone – Raymond James Operator Good afternoon. And welcome to Curis' Fourth Quarter and year- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30347 CURIS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3505116 (State or other jurisdiction of incorpora ...

Corporate Presentation NASDAQ: CRIS Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "believe(s)," "will," "may," "anticipate(s)," "focus(es)," "plans," "mission," "strategy," "potential," "estimate(s)", "intend," "project," "seek," "should," "would" and similar expressions are int ...

Financial Data and Key Metrics Changes - For Q3 2021, the company reported a net loss of $11.1 million or $0.12 per share, compared to a net loss of $6 million or $0.11 per share in Q3 2020 [32] - Revenues for Q3 2021 were $3 million, up from $2.7 million in Q3 2020, while revenues for the nine months ended September 30, 2021, were $7.5 million, down from $7.8 million in the same period in 2020 [33] - Operating expenses for Q3 2021 were $13.1 million, compared to $7.5 million in Q3 2020, with R&D expenses increasing to $8.6 million from $4.7 million in the same period [34][36] Business Line Data and Key Metrics Changes - The lead asset, CA-4948, is being evaluated in nine distinct patient populations across AML, MDS, and B cell cancers, showing a well-tolerated safety profile and improved efficacy [5][7] - CI-8993, a monoclonal anti-VISTA antibody, is currently in a Phase 1 dose escalation study for relapsed or refractory solid tumors, with initial safety data expected in January 2022 [28][30] Market Data and Key Metrics Changes - The company is focusing on the unmet needs in AML and MDS, where many patients currently only have supportive care options [5][20] - CA-4948 has shown potential in crossing the blood-brain barrier, indicating possible applications in primary central nervous system lymphoma [26] Company Strategy and Development Direction - The company aims to expand clinical investment in both monotherapy and combination therapy for CA-4948, targeting a broad spectrum of patients from low-risk MDS to high-risk AML [22] - The combination study of CA-4948 with ibrutinib is expected to enhance anti-tumor activity, with initial data anticipated in 2022 [24][60] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing studies and the potential for CA-4948 to provide a transformative treatment option for patients with AML and MDS [22][25] - The company plans to provide updates on safety and efficacy data in January 2022, which will include a larger dataset than previously presented [30][46] Other Important Information - As of September 30, 2021, the company had cash, cash equivalents, and investments totaling $149.8 million, expected to sustain operations into 2024 [40] - The company is collaborating with regulatory consultants to prepare for discussions with the FDA regarding the potential registrational path for CA-4948 [44][45] Q&A Session Summary Question: FDA conversation timing and patient data sufficiency - Management indicated that discussions with the FDA would likely occur after a more robust data update, aiming for 10 to 20 patients by year-end [42][44] Question: Safety of the ibrutinib combination - Management confirmed that there were no dose-limiting toxicities observed in the combination study, indicating good tolerability [47][48] Question: Expectations for B-cell cancer combo data - Management noted that while specific response rates have not been set, they hope to see durable responses and deeper responses than with BTK inhibitors alone [61] Question: Natural history of MDS and response rates - Management explained that spliceosome mutations occur early in MDS progression and that response rates vary significantly across disease stages [65][67]

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact N ...

Curis, Inc. (NASDAQ:CRIS) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Bill Steinkrauss – Chief Financial Officer Jim Dentzer – President and Chief Executive Officer Bob Martell – Head of R&D Conference Call Participants Justin Walsh – B. Riley Securities Yale Jen – Laidlaw & Co. Operator Good afternoon and welcome to the Curis Second Quarter 2021 Earnings Call. All participants will be in a listen-only mode. [Operator instructions] After the company's prepared remarks, ca ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name o ...

Curis, Inc. (NASDAQ:CRIS) Q1 2021 Results Conference Call May 12, 2021 4:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President and Chief Executive Officer Bob Martell - Head of Research and Development Conference Call Participants Ed White - H.C. Wainwright Justin Walsh - B. Riley Securities Soumit Roy - JonesTrading Alethia Young - Cantor Fitzgerald Operator Good afternoon and welcome to the Curis' First Quarter 2021 Earnings Call. All participants will be in a li ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.01 per share CRIS Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Corporate Presentation NASDAQ: CRIS Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ("we," "us," or the "Company") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "expect(s)," "believe(s)," "will," "may," "anticipate(s)," "focus(es)," "plans," "mission," "strategy," "potential," "estimate(s)", "intend," "project," "seek," "should," "would" and similar expressions are int ...